FDA advisory panel votes to recommend allowing six unproven peptides for compounding pharmacies

An FDA advisory panel has voted to recommend adding six unproven peptides to the list of custom drugs that compounding pharmacies can sell, sparking a fierce debate over safety, regulation, and consumer demand.

The Vote and Its Controversial Backdrop

According to Tom Bartlett in The Atlantic, the panel's vote last month has raised alarms. Peptides are chains of amino acids that instruct cells to regulate biological processes; some, like insulin and GLP-1s, are FDA-approved medicines. However, pharmacies were banned in 2023 from dispensing these six specific peptides—which proponents claim offer benefits ranging from improved endurance to reduced inflammation—due to efficacy and safety concerns.

That ban frustrated Health Secretary Robert F. Kennedy Jr., a known peptides enthusiast. Ahead of the vote, Kennedy added eight new members to the panel, six of whom run clinics that offer the chemicals. While the vote is only a recommendation, "ultimate approval seems likely"—to the delight of sellers anticipating a "peptide gold rush" and the horror of experts who fear we are opening a "Pandora's box."

Surging Demand and the Gray Market

Demand for injectable peptides is surging, "thanks to the endorsement of podcasters, wellness influencers," and celebrities, reports Emily Mullin in Wired. Among the chemicals approved by the panel are two that combine to form the Joe Rogan–backed "Wolverine stack," which supposedly aids in injury recovery.

Undeterred by the lack of evidence, users currently buy peptides on the "unregulated gray market." The chemicals are sourced from labs in China and India and sold as "for research use only."

A Deep Divide Between Kennedy Appointees and FDA Scientists

The vote "exposed a deep divide" between Kennedy's appointees and FDA scientists, according to Yonathan Daniel in ABCNews.com. Scientists cited the absence of clinical trial data and the possibility of harmful immune reactions. Proponents, however, argued that thousands of people already take potentially dangerous black market peptides, and that the agency should protect them by granting access to safer products.

Broader Implications for FDA Standards

This isn't "just about peptides," writes Julia Belluz in The New York Times. It is "part of a broader push" to increase access to drugs that haven't met "the strict evidence standards the FDA usually requires." The agency "wasn't designed for this wellness-crazed" telehealth era, in which Americans are "going outside the bounds of traditional health care in growing numbers."

But the FDA is "the only thing standing between consumers and a Wild West market" for untested and potentially harmful drugs. "There has to be a better way forward" than dropping standards and allowing consumer demand to override "scientific evidence."

This article was adapted from reporting in The Atlantic, Wired, ABCNews.com, and The New York Times, as compiled by The Week.